NRx Pharmaceuticals, Lotus Pharmaceuticals And Alvogen Inc. Announce Collaboration To Develop And Commercialize NRX-101; NRx Eligible To Receive Up To $330M In Milestone Payments, Lotus To Acquire Worldwide Rights For NRX-101 For S-TRBD
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen Inc. have announced a collaboration to develop and commercialize NRX-101, with NRx eligible to receive up to $330 million in milestone payments. Lotus will acquire worldwide rights for NRX-101 for S-TRBD.

June 05, 2023 | 11:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NRx Pharmaceuticals is eligible to receive up to $330 million in milestone payments from its collaboration with Lotus Pharmaceuticals and Alvogen Inc. to develop and commercialize NRX-101.
The collaboration between NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen Inc. to develop and commercialize NRX-101 is a significant partnership for NRx. The potential milestone payments of up to $330 million will provide a substantial revenue stream for the company, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100